nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.0301	0.258	CbGpPWpGaD
Fluocinonide—Dermatitis perioral—Tretinoin—peripheral nervous system neoplasm	0.0235	0.0267	CcSEcCtD
Fluocinonide—Dermatitis perioral—Isotretinoin—peripheral nervous system neoplasm	0.0235	0.0267	CcSEcCtD
Fluocinonide—Telangiectasia—Tretinoin—peripheral nervous system neoplasm	0.0226	0.0258	CcSEcCtD
Fluocinonide—Telangiectasia—Isotretinoin—peripheral nervous system neoplasm	0.0226	0.0258	CcSEcCtD
Fluocinonide—Acneiform eruption—Tretinoin—peripheral nervous system neoplasm	0.0211	0.024	CcSEcCtD
Fluocinonide—Acneiform eruption—Isotretinoin—peripheral nervous system neoplasm	0.0211	0.024	CcSEcCtD
Fluocinonide—Miliaria—Tretinoin—peripheral nervous system neoplasm	0.0181	0.0207	CcSEcCtD
Fluocinonide—Miliaria—Isotretinoin—peripheral nervous system neoplasm	0.0181	0.0207	CcSEcCtD
Fluocinonide—Secondary infection—Tretinoin—peripheral nervous system neoplasm	0.0181	0.0207	CcSEcCtD
Fluocinonide—Secondary infection—Isotretinoin—peripheral nervous system neoplasm	0.0181	0.0207	CcSEcCtD
Fluocinonide—Dermatitis perioral—Alitretinoin—peripheral nervous system neoplasm	0.0178	0.0203	CcSEcCtD
Fluocinonide—Skin atrophy—Tretinoin—peripheral nervous system neoplasm	0.0177	0.0201	CcSEcCtD
Fluocinonide—Skin atrophy—Isotretinoin—peripheral nervous system neoplasm	0.0177	0.0201	CcSEcCtD
Fluocinonide—Telangiectasia—Alitretinoin—peripheral nervous system neoplasm	0.0172	0.0195	CcSEcCtD
Fluocinonide—Skin striae—Tretinoin—peripheral nervous system neoplasm	0.0168	0.0191	CcSEcCtD
Fluocinonide—Skin striae—Isotretinoin—peripheral nervous system neoplasm	0.0168	0.0191	CcSEcCtD
Fluocinonide—Acneiform eruption—Alitretinoin—peripheral nervous system neoplasm	0.016	0.0182	CcSEcCtD
Fluocinonide—Dermatitis acneiform—Tretinoin—peripheral nervous system neoplasm	0.0156	0.0178	CcSEcCtD
Fluocinonide—Dermatitis acneiform—Isotretinoin—peripheral nervous system neoplasm	0.0156	0.0178	CcSEcCtD
Fluocinonide—Allergic contact dermatitis—Tretinoin—peripheral nervous system neoplasm	0.0153	0.0174	CcSEcCtD
Fluocinonide—Allergic contact dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.0153	0.0174	CcSEcCtD
Fluocinonide—Secondary infection—Alitretinoin—peripheral nervous system neoplasm	0.0138	0.0157	CcSEcCtD
Fluocinonide—Miliaria—Alitretinoin—peripheral nervous system neoplasm	0.0138	0.0157	CcSEcCtD
Fluocinonide—Skin atrophy—Alitretinoin—peripheral nervous system neoplasm	0.0134	0.0152	CcSEcCtD
Fluocinonide—Skin striae—Alitretinoin—peripheral nervous system neoplasm	0.0127	0.0145	CcSEcCtD
Fluocinonide—Leukoderma—Tretinoin—peripheral nervous system neoplasm	0.0125	0.0143	CcSEcCtD
Fluocinonide—Leukoderma—Isotretinoin—peripheral nervous system neoplasm	0.0125	0.0143	CcSEcCtD
Fluocinonide—Application site pain—Isotretinoin—peripheral nervous system neoplasm	0.0121	0.0138	CcSEcCtD
Fluocinonide—Application site pain—Tretinoin—peripheral nervous system neoplasm	0.0121	0.0138	CcSEcCtD
Fluocinonide—Dermatitis acneiform—Alitretinoin—peripheral nervous system neoplasm	0.0118	0.0135	CcSEcCtD
Fluocinonide—Allergic contact dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.0116	0.0132	CcSEcCtD
Fluocinonide—Application site reaction—Isotretinoin—peripheral nervous system neoplasm	0.0114	0.0129	CcSEcCtD
Fluocinonide—Application site reaction—Tretinoin—peripheral nervous system neoplasm	0.0114	0.0129	CcSEcCtD
Fluocinonide—Leukoderma—Alitretinoin—peripheral nervous system neoplasm	0.00951	0.0108	CcSEcCtD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—CD55—peripheral nervous system neoplasm	0.00942	0.0808	CbGpPWpGaD
Fluocinonide—Application site pain—Alitretinoin—peripheral nervous system neoplasm	0.00919	0.0105	CcSEcCtD
Fluocinonide—Application site reaction—Alitretinoin—peripheral nervous system neoplasm	0.00862	0.00981	CcSEcCtD
Fluocinonide—Folliculitis—Tretinoin—peripheral nervous system neoplasm	0.00849	0.00966	CcSEcCtD
Fluocinonide—Folliculitis—Isotretinoin—peripheral nervous system neoplasm	0.00849	0.00966	CcSEcCtD
Fluocinonide—Eruption—Dactinomycin—peripheral nervous system neoplasm	0.00709	0.00807	CcSEcCtD
Fluocinonide—Folliculitis—Dactinomycin—peripheral nervous system neoplasm	0.00694	0.00789	CcSEcCtD
Fluocinonide—Folliculitis—Alitretinoin—peripheral nervous system neoplasm	0.00643	0.00732	CcSEcCtD
Fluocinonide—Secondary infection—Epirubicin—peripheral nervous system neoplasm	0.00602	0.00685	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—peripheral nervous system neoplasm	0.00557	0.00634	CcSEcCtD
Fluocinonide—Dermatitis contact—Tretinoin—peripheral nervous system neoplasm	0.00527	0.006	CcSEcCtD
Fluocinonide—Dermatitis contact—Isotretinoin—peripheral nervous system neoplasm	0.00527	0.006	CcSEcCtD
Fluocinonide—Skin exfoliation—Isotretinoin—peripheral nervous system neoplasm	0.00509	0.0058	CcSEcCtD
Fluocinonide—Skin exfoliation—Tretinoin—peripheral nervous system neoplasm	0.00509	0.0058	CcSEcCtD
Fluocinonide—Skin exfoliation—Melphalan—peripheral nervous system neoplasm	0.00503	0.00572	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00502	0.043	CbGpPWpGaD
Fluocinonide—Swelling—Isotretinoin—peripheral nervous system neoplasm	0.00439	0.00499	CcSEcCtD
Fluocinonide—Swelling—Tretinoin—peripheral nervous system neoplasm	0.00439	0.00499	CcSEcCtD
Fluocinonide—Nasal congestion—Isotretinoin—peripheral nervous system neoplasm	0.00425	0.00484	CcSEcCtD
Fluocinonide—Nasal congestion—Tretinoin—peripheral nervous system neoplasm	0.00425	0.00484	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—peripheral nervous system neoplasm	0.00416	0.00473	CcSEcCtD
Fluocinonide—Dermatitis contact—Alitretinoin—peripheral nervous system neoplasm	0.00399	0.00455	CcSEcCtD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—GNAS—peripheral nervous system neoplasm	0.00386	0.0331	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Alitretinoin—peripheral nervous system neoplasm	0.00386	0.00439	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—peripheral nervous system neoplasm	0.00385	0.00438	CcSEcCtD
Fluocinonide—Dry skin—Tretinoin—peripheral nervous system neoplasm	0.00355	0.00404	CcSEcCtD
Fluocinonide—Dry skin—Isotretinoin—peripheral nervous system neoplasm	0.00355	0.00404	CcSEcCtD
Fluocinonide—SMO—Hedgehog 'off' state—GNAS—peripheral nervous system neoplasm	0.00351	0.0301	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Isotretinoin—peripheral nervous system neoplasm	0.00346	0.00394	CcSEcCtD
Fluocinonide—Nasopharyngitis—Tretinoin—peripheral nervous system neoplasm	0.00346	0.00394	CcSEcCtD
Fluocinonide—Swelling—Alitretinoin—peripheral nervous system neoplasm	0.00333	0.00379	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—GNAS—peripheral nervous system neoplasm	0.00329	0.0282	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Cisplatin—peripheral nervous system neoplasm	0.00329	0.00374	CcSEcCtD
Fluocinonide—Nasal congestion—Alitretinoin—peripheral nervous system neoplasm	0.00322	0.00367	CcSEcCtD
Fluocinonide—SMO—Signaling by Hedgehog—GNAS—peripheral nervous system neoplasm	0.00313	0.0268	CbGpPWpGaD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	0.00311	0.0267	CbGpPWpGaD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—AKT1—peripheral nervous system neoplasm	0.00302	0.0259	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Etoposide—peripheral nervous system neoplasm	0.00301	0.00343	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—NTS—peripheral nervous system neoplasm	0.00295	0.0253	CbGpPWpGaD
Fluocinonide—Eruption—Epirubicin—peripheral nervous system neoplasm	0.00288	0.00327	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00284	0.0243	CbGpPWpGaD
Fluocinonide—Folliculitis—Epirubicin—peripheral nervous system neoplasm	0.00281	0.0032	CcSEcCtD
Fluocinonide—Nasal congestion—Cisplatin—peripheral nervous system neoplasm	0.00274	0.00312	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—MYC—peripheral nervous system neoplasm	0.00269	0.0231	CbGpPWpGaD
Fluocinonide—Dry skin—Alitretinoin—peripheral nervous system neoplasm	0.00269	0.00306	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00269	0.023	CbGpPWpGaD
Fluocinonide—Eruption—Doxorubicin—peripheral nervous system neoplasm	0.00266	0.00303	CcSEcCtD
Fluocinonide—Nasopharyngitis—Alitretinoin—peripheral nervous system neoplasm	0.00262	0.00299	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—peripheral nervous system neoplasm	0.0026	0.00296	CcSEcCtD
Fluocinonide—Swelling—Etoposide—peripheral nervous system neoplasm	0.0026	0.00295	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00258	0.0221	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.00246	0.0211	CbGpPWpGaD
Fluocinonide—Immune system disorder—Topotecan—peripheral nervous system neoplasm	0.00244	0.00278	CcSEcCtD
Fluocinonide—Immune system disorder—Melphalan—peripheral nervous system neoplasm	0.00239	0.00272	CcSEcCtD
Fluocinonide—Erythema—Tretinoin—peripheral nervous system neoplasm	0.00233	0.00265	CcSEcCtD
Fluocinonide—Erythema—Isotretinoin—peripheral nervous system neoplasm	0.00233	0.00265	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.00224	0.0192	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Cisplatin—peripheral nervous system neoplasm	0.00224	0.00254	CcSEcCtD
Fluocinonide—Glycosuria—Epirubicin—peripheral nervous system neoplasm	0.00218	0.00248	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.00205	0.0176	CbGpPWpGaD
Fluocinonide—Glycosuria—Doxorubicin—peripheral nervous system neoplasm	0.00202	0.0023	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.00202	0.0173	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—peripheral nervous system neoplasm	0.00199	0.00226	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Tretinoin—peripheral nervous system neoplasm	0.00197	0.00224	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Isotretinoin—peripheral nervous system neoplasm	0.00197	0.00224	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Melphalan—peripheral nervous system neoplasm	0.00195	0.00221	CcSEcCtD
Fluocinonide—Erythema—Dactinomycin—peripheral nervous system neoplasm	0.00191	0.00217	CcSEcCtD
Fluocinonide—Infection—Topotecan—peripheral nervous system neoplasm	0.00191	0.00217	CcSEcCtD
Fluocinonide—Infection—Isotretinoin—peripheral nervous system neoplasm	0.00189	0.00215	CcSEcCtD
Fluocinonide—Infection—Tretinoin—peripheral nervous system neoplasm	0.00189	0.00215	CcSEcCtD
Fluocinonide—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.00188	0.00214	CcSEcCtD
Fluocinonide—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.00187	0.00212	CcSEcCtD
Fluocinonide—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.00187	0.00212	CcSEcCtD
Fluocinonide—Infection—Melphalan—peripheral nervous system neoplasm	0.00187	0.00212	CcSEcCtD
Fluocinonide—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.00186	0.00212	CcSEcCtD
Fluocinonide—Triamcinolone—BCHE—peripheral nervous system neoplasm	0.00185	0.391	CrCbGaD
Fluocinonide—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.00185	0.0021	CcSEcCtD
Fluocinonide—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.00185	0.0021	CcSEcCtD
Fluocinonide—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.00182	0.00208	CcSEcCtD
Fluocinonide—Erythema—Alitretinoin—peripheral nervous system neoplasm	0.00177	0.00201	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—peripheral nervous system neoplasm	0.00175	0.00199	CcSEcCtD
Fluocinonide—Skin exfoliation—Epirubicin—peripheral nervous system neoplasm	0.00169	0.00192	CcSEcCtD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—AKT1—peripheral nervous system neoplasm	0.00168	0.0144	CbGpPWpGaD
Fluocinonide—Pain—Topotecan—peripheral nervous system neoplasm	0.00164	0.00187	CcSEcCtD
Fluocinonide—Pain—Tretinoin—peripheral nervous system neoplasm	0.00163	0.00185	CcSEcCtD
Fluocinonide—Pain—Isotretinoin—peripheral nervous system neoplasm	0.00163	0.00185	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—peripheral nervous system neoplasm	0.00162	0.00184	CcSEcCtD
Fluocinonide—Pain—Melphalan—peripheral nervous system neoplasm	0.00161	0.00183	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—peripheral nervous system neoplasm	0.00156	0.00178	CcSEcCtD
Fluocinonide—Immune system disorder—Cisplatin—peripheral nervous system neoplasm	0.00156	0.00178	CcSEcCtD
Fluocinonide—Infection—Dactinomycin—peripheral nervous system neoplasm	0.00155	0.00176	CcSEcCtD
Fluocinonide—Erythema—Cisplatin—peripheral nervous system neoplasm	0.00151	0.00171	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.00149	0.0017	CcSEcCtD
Fluocinonide—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00143	0.00163	CcSEcCtD
Fluocinonide—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.00143	0.00163	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—TH—peripheral nervous system neoplasm	0.00142	0.0122	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00141	0.00161	CcSEcCtD
Fluocinonide—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.00141	0.00161	CcSEcCtD
Fluocinonide—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.0014	0.0016	CcSEcCtD
Fluocinonide—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.0014	0.0016	CcSEcCtD
Fluocinonide—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.0014	0.00159	CcSEcCtD
Fluocinonide—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00138	0.00157	CcSEcCtD
Fluocinonide—Infection—Vincristine—peripheral nervous system neoplasm	0.00138	0.00157	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00138	0.0118	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.00136	0.00155	CcSEcCtD
Fluocinonide—Pruritus—Topotecan—peripheral nervous system neoplasm	0.00136	0.00154	CcSEcCtD
Fluocinonide—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00135	0.00153	CcSEcCtD
Fluocinonide—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00135	0.00153	CcSEcCtD
Fluocinonide—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00133	0.00151	CcSEcCtD
Fluocinonide—Pruritus—Melphalan—peripheral nervous system neoplasm	0.00133	0.00151	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00132	0.0113	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IFNB1—peripheral nervous system neoplasm	0.00127	0.0109	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00127	0.00145	CcSEcCtD
Fluocinonide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00127	0.00144	CcSEcCtD
Fluocinonide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00126	0.00143	CcSEcCtD
Fluocinonide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00126	0.00143	CcSEcCtD
Fluocinonide—Pain—Alitretinoin—peripheral nervous system neoplasm	0.00123	0.0014	CcSEcCtD
Fluocinonide—Infection—Cisplatin—peripheral nervous system neoplasm	0.00122	0.00139	CcSEcCtD
Fluocinonide—Rash—Topotecan—peripheral nervous system neoplasm	0.00121	0.00138	CcSEcCtD
Fluocinonide—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00121	0.00138	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00121	0.0103	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.0012	0.00137	CcSEcCtD
Fluocinonide—Headache—Topotecan—peripheral nervous system neoplasm	0.0012	0.00137	CcSEcCtD
Fluocinonide—Rash—Tretinoin—peripheral nervous system neoplasm	0.0012	0.00137	CcSEcCtD
Fluocinonide—Rash—Isotretinoin—peripheral nervous system neoplasm	0.0012	0.00137	CcSEcCtD
Fluocinonide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.0012	0.00136	CcSEcCtD
Fluocinonide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.0012	0.00136	CcSEcCtD
Fluocinonide—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.00119	0.00136	CcSEcCtD
Fluocinonide—Headache—Tretinoin—peripheral nervous system neoplasm	0.00119	0.00136	CcSEcCtD
Fluocinonide—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00119	0.00136	CcSEcCtD
Fluocinonide—Pain—Vincristine—peripheral nervous system neoplasm	0.00119	0.00135	CcSEcCtD
Fluocinonide—Rash—Melphalan—peripheral nervous system neoplasm	0.00118	0.00135	CcSEcCtD
Fluocinonide—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00118	0.00135	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.00118	0.00134	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00117	0.00133	CcSEcCtD
Fluocinonide—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.00115	0.00131	CcSEcCtD
Fluocinonide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00115	0.0013	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.00113	0.00969	CbGpPWpGaD
Fluocinonide—Infection—Etoposide—peripheral nervous system neoplasm	0.00112	0.00127	CcSEcCtD
Fluocinonide—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.00109	0.00124	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.00109	0.00124	CcSEcCtD
Fluocinonide—Fluticasone furoate—ABCB1—peripheral nervous system neoplasm	0.00108	0.228	CrCbGaD
Fluocinonide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00106	0.00121	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.00106	0.00121	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00106	0.00905	CbGpPWpGaD
Fluocinonide—Pain—Cisplatin—peripheral nervous system neoplasm	0.00105	0.0012	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00104	0.00896	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.00103	0.0088	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00102	0.00117	CcSEcCtD
Fluocinonide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.00102	0.00116	CcSEcCtD
Fluocinonide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.001	0.00114	CcSEcCtD
Fluocinonide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000981	0.00112	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000964	0.00827	CbGpPWpGaD
Fluocinonide—Pain—Etoposide—peripheral nervous system neoplasm	0.000963	0.0011	CcSEcCtD
Fluocinonide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000954	0.00109	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000926	0.00105	CcSEcCtD
Fluocinonide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000919	0.00105	CcSEcCtD
Fluocinonide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000909	0.00103	CcSEcCtD
Fluocinonide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000908	0.00103	CcSEcCtD
Fluocinonide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000905	0.00103	CcSEcCtD
Fluocinonide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000903	0.00103	CcSEcCtD
Fluocinonide—Rash—Vincristine—peripheral nervous system neoplasm	0.000876	0.000997	CcSEcCtD
Fluocinonide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000875	0.000996	CcSEcCtD
Fluocinonide—Headache—Vincristine—peripheral nervous system neoplasm	0.000871	0.000991	CcSEcCtD
Fluocinonide—Methylprednisolone—ABCB1—peripheral nervous system neoplasm	0.00086	0.182	CrCbGaD
Fluocinonide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000829	0.000944	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000817	0.00701	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000814	0.00698	CbGpPWpGaD
Fluocinonide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000802	0.000913	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000801	0.00687	CbGpPWpGaD
Fluocinonide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000796	0.000906	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000781	0.00669	CbGpPWpGaD
Fluocinonide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000775	0.000882	CcSEcCtD
Fluocinonide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000774	0.000881	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000773	0.00088	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000749	0.00642	CbGpPWpGaD
Fluocinonide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000744	0.000847	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000742	0.000845	CcSEcCtD
Fluocinonide—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000715	0.000814	CcSEcCtD
Fluocinonide—Rash—Etoposide—peripheral nervous system neoplasm	0.00071	0.000808	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000709	0.000807	CcSEcCtD
Fluocinonide—Headache—Etoposide—peripheral nervous system neoplasm	0.000705	0.000803	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000667	0.00571	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000658	0.00564	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000654	0.000744	CcSEcCtD
Fluocinonide—Infection—Epirubicin—peripheral nervous system neoplasm	0.000627	0.000713	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000619	0.00531	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000619	0.000704	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000617	0.00529	CbGpPWpGaD
Fluocinonide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000613	0.000698	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00061	0.00523	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000605	0.000688	CcSEcCtD
Fluocinonide—Betamethasone—ABCB1—peripheral nervous system neoplasm	0.000594	0.126	CrCbGaD
Fluocinonide—Infection—Doxorubicin—peripheral nervous system neoplasm	0.00058	0.00066	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000573	0.000652	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00057	0.00488	CbGpPWpGaD
Fluocinonide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000567	0.000645	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000555	0.00476	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000542	0.00464	CbGpPWpGaD
Fluocinonide—Pain—Epirubicin—peripheral nervous system neoplasm	0.00054	0.000614	CcSEcCtD
Fluocinonide—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000499	0.000568	CcSEcCtD
Fluocinonide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000465	0.000529	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	0.000454	0.00389	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000452	0.00387	CbGpPWpGaD
Fluocinonide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000446	0.000508	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—EED—peripheral nervous system neoplasm	0.000438	0.00375	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.00043	0.00049	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000428	0.00367	CbGpPWpGaD
Fluocinonide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000417	0.000475	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000413	0.00047	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.000402	0.00345	CbGpPWpGaD
Fluocinonide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000398	0.000453	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000397	0.000452	CcSEcCtD
Fluocinonide—Headache—Epirubicin—peripheral nervous system neoplasm	0.000395	0.00045	CcSEcCtD
Fluocinonide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000386	0.000439	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000376	0.00323	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—peripheral nervous system neoplasm	0.000371	0.00318	CbGpPWpGaD
Fluocinonide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000368	0.000419	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000368	0.000419	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000366	0.00314	CbGpPWpGaD
Fluocinonide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.000416	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.00035	0.003	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000349	0.00299	CbGpPWpGaD
Fluocinonide—Dexamethasone—ABCB1—peripheral nervous system neoplasm	0.000346	0.0731	CrCbGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—peripheral nervous system neoplasm	0.000327	0.0028	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.00032	0.00274	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000305	0.00261	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	0.000279	0.00239	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—peripheral nervous system neoplasm	0.000276	0.00237	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000226	0.00194	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000222	0.00191	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000176	0.00151	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000166	0.00142	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.00016	0.00137	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000146	0.00125	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000134	0.00115	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000125	0.00107	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000102	0.000877	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.000101	0.000862	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.78e-05	0.000839	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.64e-05	0.000741	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—peripheral nervous system neoplasm	4.84e-05	0.000415	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—AKT1—peripheral nervous system neoplasm	3.36e-05	0.000288	CbGpPWpGaD
